1"use strict";(self.webpackChunkgatsby_wp_starter=self.webpackChunkgatsby_wp_starter||[]).push([[28],{50229:function(e,o,t){t.r(o);t(67294);var n=t(95181),a=t(83479),i=t(56913),r=t(80940),s=t(62105),l=t(84476),c=t(32679),m=t(14144),d=t(31819),p=t(54372),u=t(40244),g=t(28565),h=t(73821),y=t(58305),f=t(91761),v=t(77353),C=(t(6094),t(89068)),b=t(4382);o.default=function(){var e=(0,s.useStaticQuery)("242591006");return(0,b.jsx)(n.Z,{variation:"about",seo:{title:"Layouts - ONLY FOR DEV",metaRobotsNoindex:"noindex",metaRobotsNofollow:"nofollow"}},(0,b.jsx)(i.$S,null,"MiscContent"),(0,b.jsx)(a.Z,{content:"<p>Some content Here</p>"}),(0,b.jsx)(i.$S,null,"Pipeline Hero"),(0,b.jsx)(m.Z,{title:"Meet our team of drug hunters, researchers, and engineers all working together to improve the way we do drug discovery.",smoothImage:e.moleculeSpipe,image:e.moleculePipe}),(0,b.jsx)(i.$S,null,"Pipeline Table"),(0,b.jsx)(p.Z,{title:"The PostEra Pipeline",tableItems:[{indication:"COVID",phaseProgress:"75",partner:"Moonshot",rights:"IP - Free"},{indication:"COVID",phaseProgress:"25",partner:"Pfizer",rights:"Royalties + Milestones"},{indication:"Pandemic Preparedness",phaseProgress:"15",partner:"NIH",rights:"IP - Free"},{indication:"Oncology",phaseProgress:"10",partner:"Pfizer",rights:"Royalties + Milestones"},{indication:"Coming Soon",partner:"Internal",rights:"Wholly-Owned"},{indication:"Coming Soon",partner:"Internal",rights:"Wholly-Owned"},{indication:"Coming Soon",partner:"Internal",rights:"Wholly-Owned"}]}),(0,b.jsx)(i.$S,null,"Map Markers"),(0,b.jsx)(h.Z,{mapImage:e.worldMap,title:"In March 2020 PostEra helped launch COVID Moonshot, which became the worldâs largest open-science initiative to develop a COVID antiviral cure.",description:"With low and middle income economies limited in access to vaccines, Moonshot set out to develop patent-free compounds that would be readily accessible for all patients around the world.",mapPoints:[{lat:23.424076,lng:53.847818,content:"University of North Carolina<br />United States<br /><span>Antiviral Assays</span>"},{lat:-11.202692,lng:17.873887,content:"University of North Carolina<br />United States<br /><span>Antiviral Assays</span>"},{lat:-38.416097,lng:-63.616672,content:"University of North Carolina<br />United States<br /><span>Antiviral Assays</span>"}]}),(0,b.jsx)(i.$S,null,"Info Grid"),(0,b.jsx)(y.Z,{title:"PostEraâs machine learning drove the prioritization of crowdsourced ideas ",description:'Moonshot crowdsourced antiviral ideas, inspired by a fragment screen, from over 400 scientists around the world. \n PostEraâs machine learning drove the prioritization of these ideas and designed the synthesis of all 2000 \n compounds made as part of COVID Moonshot as well as using our ML technology to develop new \n <a href="/">chemotypes.</a>'}),(0,b.jsx)(i.$S,null,"Project Table"),(0,b.jsx)(f.Z,{description:"In 18 months, the project progressed from a fragment screen to the nomination of Development Candidates ready for IND-enabling studies.",tableItems:[{property:"Protese Assay",targetRange:"IC50 < 50 nM",results:"40 nM"},{property:"Viral Replication",targetRange:"EC50 < 0.2 µM",results:"0.15 µM in A549 CPE"},{property:"PK-PD",targetRange:"Cmin > EC90 (Plaque deriction) for 24h",results:"Current Projected human doce ~220mg QD; 100mg BID"},{property:"Coronavirus Spectrum",targetRange:"SARS-CoV2 B1.1.7, 501.V2, B.1.1.248 variants essential",results:"Active against B1.1.7, 501.V2 in cellular assays"},{property:"Route of Administration",targetRange:"Oral",results:"BO = 45% in rat"},{property:"Solubility",targetRange:"> 5 ,g/mL, > 100 µM tolerable",results:"0.15 µM in A549 CPE"},{property:"Half-Life",targetRange:"ideally > = 8h(human) est from rat and dog",results:"Rat 2h, human predicted PK suffiente"},{property:"Safety",targetRange:"No significant proteae activity > 50% at 10µM (Nanosyn 61 protese panel)\n Only reversible and monitorable toxicities (NOAEL > 30x Cmax)\n No significant DDI - clean in 5 CYP$%) isoforms\n Critical transportes check (e.g OATP)\n hERG and NaV1.5 IC50 > 50 µM\n No significant change in QTc\n No Mutagenicity or teratogenicity risk",results:"\n Protease panel clean on analogues\n Eurofins / CEREP 44 target panel clean\n Cyp450: clean except 2A4
1(3uM)\n No hERG activity \n Live phase planned\n Lead compounds are clean in AMES +/- S9"}],whatsNext:[{title:"What´s next",items:[{title:"$11M",description:"Moonshot attracted an $11M grant to move our patent-free compounds through IND-enabling studies and into clinical trials."},{title:"$68M",description:"PostEra and members of the Moonshot consortium successfully secured a $68M grant from the NIH to develop antivirals against other viruses of pandemic concern."}]}]}),(0,b.jsx)(i.$S,null,"CaseStudiesHero"),(0,b.jsx)(C.Z,{title:"COVID Moonshot: PostEraâs machine learning platform in real world drug discovery",topLabel:"CASE <br /> STUDIES",image:e.moleculeCaseS,smoothImage:e.smoothMoleculeCaseS}),(0,b.jsx)(i.$S,null,"MeetTeam"),(0,b.jsx)(r.Z,{title:"Meet the Team",employees:[{name:"Jhon Doe 0",occupation:"Founder and CEO",image:e.employeeImg},{name:"Jhon Doe 1",occupation:"Founder and CEO",image:e.employeeImg},{name:"Jhon Doe 2",occupation:"Founder and CEO",image:e.employeeImg},{name:"Jhon Doe 3",occupation:"Founder and CEO",image:e.employeeImg},{name:"Jhon Doe 4",occupation:"Founder and CEO",image:e.employeeImg}]}),(0,b.jsx)(i.$S,null,"PartnersSlider"),(0,b.jsx)(l.Z,{moleculaImage:e.moleculaImage,logos:[{logo:e.logoSlider3},{logo:e.logoSlider5},{logo:e.logoSlider4},{logo:e.logoSlider2},{logo:e.logoSlider6},{logo:e.logoSlider1},{logo:e.logoSlider7}],title:"Our Drug Discovery Partners"}),(0,b.jsx)(i.$S,null,"AboutHero"),(0,b.jsx)(c.Z,{txtLabel:"The<br>Problem",extraText:"The discovery of a cure follows three stages",steps:[{name:"Biology",description:"Identify relevant biological target(s) associated with the disease."},{name:"Chemestry",description:"Develop safe and effective chemical compounds that can hit those targets."},{name:"Medicine",description:"Develop these compounds into medicines by showing their effectiveness in the appropriate patients in clinical trials."}],title:"Developing cures for diseases has a high rate of failure, is very time consuming, and very expensive.",moleculaImage:e.moleculaAbout}),(0,b.jsx)(i.$S,null,"Publications Slider"),(0,b.jsx)(d.Z,{title:"Our Technology is not a black box",description:"Weâve partnered with the worldâs top pharmaceutical companies to validate our approach.",publications:[{title:"How do we train models that know what they don't know?",image:e.imgPublications,url:"url"},{title:"Title 2",image:e.imgPublications,url:"url 2"},{title:"Title 3",image:e.imgPublications,url:"url 3"},{title:"Title 4",image:e.imgPublications,url:"url 4"}]}),(0,b.jsx)(i.$S,null,"TeamHero"),(0,b.jsx)(u.Z,{image:e.moleculeTeam,title:"Meet our team of drug hunters, researchers, and engineers all working together to improve the way we do drug discovery."}),(0,b.jsx)(i.$S,null,"GrideTeam"),(0,b.jsx)(g.Z,{team:[{name:"Jhon Doe 2",occupation:"Founder and CEO",image:e.employeeImg},{name:"Jhon Doe 3",occupation:"Founder and CEO",image:e.employeeImg},{name:"Jhon Doe 4",occupation:"Founder and CEO",image:e.employeeImg},{name:"Jhon Doe 5",occupation:"Founder and CEO",image:e.employeeImg},{name:"Jhon Doe 6",occupation:"Founder and CEO",image:e.employeeImg},{name:"Jhon Doe 7",occupation:"Founder and CEO",image:e.employeeImg},{name:"Jhon Doe 8",occupation:"Founder and CEO",image:e.employeeImg},{name:"Jhon Doe 9",occupation:"Founder and CEO",image:e.employeeImg}]}),(0,b.jsx)(i.$S,null,"JoinTeam"),(0,b.jsx)(v.Z,{title:"Join our team"}),(0,b.jsx)(i.$S,null,"AboutHero-Discovery"),(0,b.jsx)(c.Z,{withMolecules:!1,txtLabel:"CO-DISCOVERY",txtButton:"Talk to us about Co-Discovery",extraText:"Hereâs how we typically work",steps:[{description:"Identify relevant biological target(s) associated with the disease."},{description:"Develop safe and effective chemical compounds that can hit those targets."},{description:"Develop these compounds into medicines by showing their effectiveness in the appropriate patients in clinical trials."}],title:"We partner with organizations to develop small molecule drug candidates.",moleculaImage:e.moleculaAbout}))}}}]); 2//# sourceMappingURL=component---src-pages-layouts-js-d3ed362ab1a4cbb99386.js.map
Line numbers count LF bytes from the start of the resource, as the search results do. Vendor segments are library code the classifier recognised; they are stored but not indexed. Bytes are shown as Latin1 characters, one per byte.